Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 7NIH 2NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 10Gliosarcoma 7Glioblastoma 7Rectal Neoplasms 4Oropharyngeal Neoplasms 4Astrocytoma 4Head and Neck Neoplasms 3Uterine Cervical Neoplasms 2Salivary Gland Neoplasms 2Neoplasm Metastasis 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Vaginal Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms 1Pinealoma 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Ototoxicity 1Osteosarcoma 1Oligodendroglioma 1Neuroma, Acoustic 1

Interventions

Magnetic Resonance Spectroscopy 11Specimen Handling 10Cisplatin 7Radiotherapy 6Paclitaxel 4Cetuximab 4Biopsy 4pembrolizumab 3Platinum 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3ipatasertib 2cemiplimab 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Radiation 2Nivolumab 2Immunoglobulin G 2Gemcitabine 2Fluorouracil 2Fluorodeoxyglucose F18 2Disulfides 2Carboplatin 2peposertib 1fluoromisonidazole 1durvalumab 1dl1520 1cabozantinib 1atezolizumab 1advexin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Mouth Neoplasms × Radiotherapy, Intensity-Modulated × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04533750 2026-04-13

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 1 Active not recruiting
21 enrolled
Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡